

SMITH & NEPHEW PLC

3 June 2026

**NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM**

This announcement is made in accordance with the UK Market Abuse Regulation (Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).

Reason for the notification	
Initial notification /Amendment	Initial notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
Name	Smith & Nephew plc
LEI	213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
Description of the financial instrument, type of instrument	Smith & Nephew plc ordinary shares of USD 0.20 each
Identification code	ISIN: GB0009223206
Nature of the transaction	Purchase of ordinary shares through the Company's Dividend Re-Investment Plan following the 2025 final dividend payment on 27 May 2026.
Date of Transaction	2026 - 05 - 27
Place of Transaction	London Stock Exchange (XLON)

Name (Position)	Director / PDMR	Price	Volume	Aggregated information
Deepak Nath (Chief Executive Officer)	Director	11.38002	6,259.14583	N/A Single Transaction
John Rogers (Chief Financial Officer)	Director	11.38002	61.89914	N/A Single Transaction
Paul Connolly (President, Global Operations)	PDMR	11.38002	1190.0452	N/A Single Transaction
Alison Parkes (Chief Compliance Officer)	PDMR	11.38002	153.58792	N/A Single Transaction
Scott Schaffner (President, Sports Medicine)	PDMR	11.38002	2148.33828	N/A Single Transaction

Philip Horner
Deputy Company Secretary

Smith & Nephew plc

Tel: +44 (0)1923 477100

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFLFLIRAVIIR